Feasibility of the 99mTc-HYNIC-βAla-Bombesin(7–14) for detection of LNCaP prostate tumour in experimental model
Previous work revealed that 25-day tumour focus is the optimal developmental stage to assess LNCaP prostate tumour by scintigraphic images using technetium-99m ( 99m Tc)-2-hydrazinonicotinamide (HYNIC)-beta-alanine (βAla)-Bombesin (7–14) in a murine model. However, more studies are essential to eval...
Saved in:
| Published in: | Journal of radioanalytical and nuclear chemistry Vol. 305; no. 2; pp. 379 - 386 |
|---|---|
| Main Authors: | , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
Dordrecht
Springer Netherlands
01-08-2015
|
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Previous work revealed that 25-day tumour focus is the optimal developmental stage to assess LNCaP prostate tumour by scintigraphic images using technetium-99m (
99m
Tc)-2-hydrazinonicotinamide (HYNIC)-beta-alanine (βAla)-Bombesin
(7–14)
in a murine model. However, more studies are essential to evaluate the feasibility of this radiopeptide as a radiotracer for LNCaP tumours. Thus, in vitro and in vivo assays were performed and showed specific affinity of
99m
Tc-HYNIC-βAla-Bombesin
(7–14)
for LNCaP cells. Scintigraphic images and biodistribution data performed in LNCaP tumour-bearing mice revealed radiotracer accumulation in tumour focus, with only 7.6 mm. Therefore,
99m
Tc-HYNIC-βAla-Bombesin
(7–14)
was able to identify LNCaP tumour, at an early developmental stage. |
|---|---|
| AbstractList | Previous work revealed that 25-day tumour focus is the optimal developmental stage to assess LNCaP prostate tumour by scintigraphic images using technetium-99m (
99m
Tc)-2-hydrazinonicotinamide (HYNIC)-beta-alanine (βAla)-Bombesin
(7–14)
in a murine model. However, more studies are essential to evaluate the feasibility of this radiopeptide as a radiotracer for LNCaP tumours. Thus, in vitro and in vivo assays were performed and showed specific affinity of
99m
Tc-HYNIC-βAla-Bombesin
(7–14)
for LNCaP cells. Scintigraphic images and biodistribution data performed in LNCaP tumour-bearing mice revealed radiotracer accumulation in tumour focus, with only 7.6 mm. Therefore,
99m
Tc-HYNIC-βAla-Bombesin
(7–14)
was able to identify LNCaP tumour, at an early developmental stage. |
| Author | Fuscaldi, Leonardo Lima Santos, Caiubi Rodrigues de Paula de Oliveira, Mônica Cristina de Barros, André Luís Branco Cardoso, Valbert Nascimento Fernandes, Simone Odília Antunes |
| Author_xml | – sequence: 1 givenname: Leonardo Lima surname: Fuscaldi fullname: Fuscaldi, Leonardo Lima organization: Faculty of Pharmacy, Federal University of Minas Gerais – sequence: 2 givenname: André Luís Branco surname: de Barros fullname: de Barros, André Luís Branco organization: Faculty of Pharmacy, Federal University of Minas Gerais – sequence: 3 givenname: Caiubi Rodrigues de Paula surname: Santos fullname: Santos, Caiubi Rodrigues de Paula organization: Faculty of Pharmacy, Federal University of Minas Gerais – sequence: 4 givenname: Mônica Cristina surname: de Oliveira fullname: de Oliveira, Mônica Cristina organization: Faculty of Pharmacy, Federal University of Minas Gerais – sequence: 5 givenname: Simone Odília Antunes surname: Fernandes fullname: Fernandes, Simone Odília Antunes organization: Faculty of Pharmacy, Federal University of Minas Gerais – sequence: 6 givenname: Valbert Nascimento surname: Cardoso fullname: Cardoso, Valbert Nascimento email: valbertcardoso@yahoo.com.br, cardosov@farmacia.ufmg.br organization: Faculty of Pharmacy, Federal University of Minas Gerais |
| BookMark | eNp9kDFOwzAUQC1UJNrCAdg8wmCw4yS2x1JRWqkqDGVgsmLnG1IlTmWnEt24AzfhIByCk5CqzEx_-e_r_TdCA996QOiS0RtGqbiNjKpcEMoyklJOiTxBQ5ZJSRIh6QANacJzkgnOztAoxg2lVEnJhyjMoIiVqeqq2-PW4e4NsFLN2pL5y2oxJd9fk7ogd21jIFb-Svx8fLL0Grs24BI6sF3V-gO3XE2LJ7wNbeyKDnC3a9pdwJXH8L6FUDXgu6LGTVtCfY5OXVFHuPibY_Q8u19P52T5-LCYTpbEMs4lkUZymriUy94dbMZpyoygZa4yw01mcrBgkyLN8xQEU2WSOSOEFVJZx6xyfIzY8a7trWIAp7e9SBH2mlF9iKaP0XQfTR-iadkzyZGJ_a5_haA3_R--1_wH-gUgEHHs |
| CitedBy_id | crossref_primary_10_3390_ph15060728 crossref_primary_10_1016_j_biopha_2016_12_083 crossref_primary_10_1097_MNM_0000000000000505 crossref_primary_10_3389_fchem_2023_1271176 crossref_primary_10_1186_s40409_016_0070_y crossref_primary_10_1016_j_ijpharm_2019_118662 crossref_primary_10_3390_ph14050385 |
| Cites_doi | 10.2967/jnumed.110.082826 10.1016/j.urology.2004.02.036 10.1007/s00259-011-2014-7 10.3109/1061186X.2012.757772 10.1016/j.ymeth.2009.04.002 10.1038/aja.2008.44 10.1016/j.ymeth.2009.03.012 10.1016/j.bmcl.2010.08.124 10.1016/S0169-409X(98)00108-2 10.2967/jnumed.109.064444 10.1007/s00259-010-1596-9 10.1016/j.nucmedbio.2008.02.005 10.1016/j.ymeth.2009.03.021 10.1124/mol.107.033894 10.1016/S0969-8051(03)00116-1 10.1021/bc700471z 10.1016/j.ijpharm.2009.04.018 10.1016/j.acra.2012.08.005 10.1007/s10967-010-0530-8 10.1038/35094009 10.1016/j.bmcl.2011.10.016 10.1007/s00259-003-1261-7 10.1007/s00726-012-1369-9 10.1007/s00259-011-2001-z 10.1016/S0960-0760(00)00131-X 10.1016/j.apradiso.2012.06.022 10.7150/thno.4024 10.1007/s10967-014-3040-2 10.1007/s10967-012-2331-8 10.2174/138955710791112596 |
| ContentType | Journal Article |
| Copyright | Akadémiai Kiadó, Budapest, Hungary 2015 |
| Copyright_xml | – notice: Akadémiai Kiadó, Budapest, Hungary 2015 |
| DBID | AAYXX CITATION |
| DOI | 10.1007/s10967-015-4030-8 |
| DatabaseName | CrossRef |
| DatabaseTitle | CrossRef |
| DatabaseTitleList | |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Chemistry |
| EISSN | 1588-2780 |
| EndPage | 386 |
| ExternalDocumentID | 10_1007_s10967_015_4030_8 |
| GroupedDBID | --- --K -4Y -58 -5G -BR -EM -Y2 -~C .86 .GJ .VR 06C 06D 0R~ 0VY 1B1 1N0 1SB 2.D 203 28- 29L 2J2 2JN 2JY 2KG 2KM 2LR 2P1 2VQ 2~H 30V 4.4 406 408 409 40D 40E 53G 5QI 5VS 67Z 6NX 78A 8TC 8UJ 8WZ 95- 95. 95~ 96X A6W A8Z AAAVM AABHQ AABYN AAFGU AAGCJ AAHNG AAIAL AAIKT AANZL AARHV AARTL AATNV AATVU AAUCO AAUYE AAWCG AAYFA AAYIU AAYQN AAYTO ABBBX ABBXA ABDBF ABDZT ABECU ABEFU ABFGW ABFTV ABHLI ABHQN ABJNI ABJOX ABKAS ABKCH ABKTR ABMNI ABMQK ABNWP ABPTK ABQBU ABSXP ABTEG ABTHY ABTKH ABTMW ABULA ABWNU ABXPI ACBMV ACBRV ACBXY ACBYP ACGFS ACHSB ACHXU ACIGE ACIPQ ACIWK ACKNC ACMDZ ACMLO ACOKC ACOMO ACSNA ACTTH ACVWB ACWMK ADHHG ADHIR ADINQ ADKNI ADKPE ADMDM ADOXG ADRFC ADTPH ADURQ ADYFF ADZKW AEBTG AEEQQ AEFIE AEGAL AEGNC AEJHL AEJRE AEKMD AENEX AEOHA AEPYU AESKC AETLH AEVLU AEXYK AFEXP AFGCZ AFLOW AFNRJ AFQWF AFWTZ AFZKB AGAYW AGDGC AGGDS AGJBK AGMZJ AGQMX AGWIL AGWZB AGYKE AHAVH AHBYD AHKAY AHSBF AHYZX AIAKS AIIXL AILAN AIMYW AITGF AJBLW AJDOV AJGSW AJRNO AJZVZ AKQUC ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AMYQR AOCGG ARMRJ ASPBG AVWKF AXYYD AYJHY AZFZN B-. BA0 BBWZM BDATZ BGNMA CAG COF CS3 CSCUP DDRTE DL5 DNIVK DPUIP DU5 EBD EBLON EBS EIOEI EJD ESBYG ESTFP ESX FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 GQ8 GXS HF~ HG5 HG6 HMJXF HQYDN HRMNR HVGLF HZ~ I-F IAO IHE IJ- IKXTQ ITC IWAJR IXC IXD IXE IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ KDC KOV KOW L8X LLZTM M4Y MA- MET MKB ML- N2Q NB0 NDZJH NPVJJ NQ- NQJWS NU0 O9- O93 O9G O9I O9J OAM OVD P19 P9N PF0 PT4 PT5 QOK QOR QOS R4E R89 R9I RHV RIG RKA RNI RNS ROL RPX RPZ RSV RZC RZE RZK S16 S1Z S26 S27 S28 S3B SAP SCG SCLPG SCM SDH SDM SHX SISQX SJYHP SNE SNPRN SNX SOHCF SOJ SPISZ SQXTU SRMVM SSLCW STPWE SZN T13 T16 TEORI TSG TSK TSV TUC TUS U2A UG4 UNUBA UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 W4F WH7 WJK WK8 YLTOR Z45 Z5O Z7R Z7V Z7W Z7X Z7Y Z7Z Z83 Z85 Z86 Z87 Z8M Z8O Z8P Z8Q Z8T Z91 ZMTXR ZXP ~02 ~8M ~EX AACDK AAEOY AAJBT AASML AAYXX AAYZH ABAKF ACAOD ACDTI ACZOJ AEFQL AEMSY AFBBN AGJZZ AGQEE AGRTI AIGIU CITATION H13 |
| ID | FETCH-LOGICAL-c1338-8b8302f438023ec53041b70d695b3b5b6ecec2a4664e719d25fb77c789cf1c9f3 |
| IEDL.DBID | AEJHL |
| ISSN | 0236-5731 |
| IngestDate | Thu Nov 21 21:04:04 EST 2024 Sat Dec 16 12:01:30 EST 2023 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Keywords | Radiopeptide Molecular imaging Ex vivo biodistribution Bombesin Technetium-99m LNCaP prostate tumour |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c1338-8b8302f438023ec53041b70d695b3b5b6ecec2a4664e719d25fb77c789cf1c9f3 |
| PageCount | 8 |
| ParticipantIDs | crossref_primary_10_1007_s10967_015_4030_8 springer_journals_10_1007_s10967_015_4030_8 |
| PublicationCentury | 2000 |
| PublicationDate | 2015-8-00 |
| PublicationDateYYYYMMDD | 2015-08-01 |
| PublicationDate_xml | – month: 08 year: 2015 text: 2015-8-00 |
| PublicationDecade | 2010 |
| PublicationPlace | Dordrecht |
| PublicationPlace_xml | – name: Dordrecht |
| PublicationSubtitle | An International Journal Dealing with All Aspects and Applications of Nuclear Chemistry |
| PublicationTitle | Journal of radioanalytical and nuclear chemistry |
| PublicationTitleAbbrev | J Radioanal Nucl Chem |
| PublicationYear | 2015 |
| Publisher | Springer Netherlands |
| Publisher_xml | – name: Springer Netherlands |
| References | SmithCJVolkertWAHoffmanTJGastrin releasing peptide (GRP) receptor targeted radiopharmaceuticals: a concise updateNucl Med Biol2003308618681:CAS:528:DC%2BD3sXhtVWisrfE10.1016/S0969-8051(03)00116-1 de BarrosALBMotaLGFerreiraCACorrêaNCRGóesAMOliveiraMCCardosoVN99mTc-labeled bombesin analog for breast cancer identificationJ Radioanal Nucl Chem2013295208320901:CAS:528:DC%2BC3sXisF2jt7k%3D10.1007/s10967-012-2331-8 LambrechtFYDurkankÖzgürAGündüzCAvcıÇBSusluerSYIn vitro evaluation of 99mTc-EDDA/tricine-HYNIC-Q-Litorin in gastrin-releasing peptide receptor positive tumor cell linesJ Drug Target2013213833881:CAS:528:DC%2BC3sXntVajtbY%3D10.3109/1061186X.2012.757772 de BarrosALBMotaLGFerreiraCAde OliveiraMCde GóesAMCardosoVNBombesin derivative radiolabeled with technetium-99m as agent for tumor identificationBioorg Med Chem Lett2010206182618410.1016/j.bmcl.2010.08.124 EmondsKMSwinnenJVMortelmansLMottaghyFMMolecular imaging of prostate cancerMethods2009481931991:CAS:528:DC%2BD1MXmvFymtbw%3D10.1016/j.ymeth.2009.03.021 ScopinaroFDe VincentisGVarvarigouADLaurentiCIoriFRemedianiSChiariniSStellaS99mTc-bombesin detects prostate cancer and invasion of pelvic lymph nodesEur J Nucl Med Mol Imaging2003301378138210.1007/s00259-003-1261-7 Santos-CuevasCLFerro-FloresGde MurphyCARamírezFMLuna-GutiérrezMAPedraza-LópezMGarcía-BecerraROrdaz-RosadoDDesign, preparation, in vitro and in vivo evaluation of 99mTc-N2S2-Tat(49–57)-bombesin: a target-specific hybrid radiopharmaceuticalInt J Pharm200937575831:CAS:528:DC%2BD1MXmsFKntLk%3D10.1016/j.ijpharm.2009.04.018 NakashimaJTanimotoAImaiYMukaiMHoriguchiYNakagawaKOyaMOhigashiTMarumoKMuraiMEndorectal MRI for prediction of tumor site, tumor size, and local extension of prostate cancerUrology20046410110510.1016/j.urology.2004.02.036 AccardoAAlojLAurilioMMorelliGTesauroDReceptor binding peptides for target-selective delivery of nanoparticles encapsulated drugsInt J Nanomed2014915371557 National Formulary (USP 34-NF 29, 2011) US Pharmacopeia Ferro-FloresGRamírezFMMeléndez-AlafortLSantos-CuevasCLPeptides for in vivo target-specific cancer imagingMini-Rev Med Chem20101087971:CAS:528:DC%2BC3cXms1ars7s%3D10.2174/138955710791112596 MansiRWangXForrerFWaserBCescatoRGrahamKBorkowskiSReubiJCMaeckeHRDevelopment of a potent DOTA-conjugated bombesin antagonist for targeting GRPr-positive tumoursEur J Nucl Med Mol Imaging201138971071:CAS:528:DC%2BC3cXhsF2gtLvJ10.1007/s00259-010-1596-9 FeldmanBJFeldmanDThe development of androgen-independent prostate cancerNat Rev2001134451:STN:280:DC%2BD387mvVOhtg%3D%3D10.1038/35094009 ShiJJiaBLiuZYangZYuZChenKChenXLiuSWangF99mTc-labeled Bombesin(7–14)NH2 with favorable properties for SPECT imaging of colon cancerBioconjug Chem200819117011781:CAS:528:DC%2BD1cXmtFWhu70%3D10.1021/bc700471z FaintuchBLTeodoroRDuattiAMuramotoEFaintuchSSmithCJRadiolabeled bombesin analogs for prostate cancer diagnosis: preclinical studiesNucl Med Biol2008354014111:CAS:528:DC%2BD1cXlvF2qt7o%3D10.1016/j.nucmedbio.2008.02.005 PhillipsWTDelivery of gamma-imaging agents by liposomesAdv Drug Deliv Rev19993713321:CAS:528:DyaK1MXis1alt7s%3D10.1016/S0169-409X(98)00108-2 YuSLaiKXiaSChangHChangCYehSThe diverse and contrasting effects of using human prostate cancer cell lines to study androgen receptor roles in prostate cancerAsian J Androl20091139481:CAS:528:DC%2BD1MXnvFCru7s%3D10.1038/aja.2008.44 XieYWolffDWLinMTuYVasoactive intestinal peptide transactivates the androgen receptor through a protein kinase A-dependent extracellular signal-regulated kinase pathway in prostate cancer LNCaP cellsMol Pharmacol20077273851:CAS:528:DC%2BD2sXnsVyjsLw%3D10.1124/mol.107.033894 FuscaldiLLde BarrosALBSantosCRPde SouzaCMCassaliGDde OliveiraMCFernandesSOACardosoVNEvaluation of the optimal LNCaP prostate tumour developmental stage to be assessed by 99mTc-HYNIC-βAla-Bombesin(7-14) in an experimental modelJ Radioanal Nucl Chem20143008018071:CAS:528:DC%2BC2cXjtlGlurw%3D10.1007/s10967-014-3040-2 KongFZhangYYoungDPYuDYangDJDevelopment of 99mTc-EC-tyrosine for early detection of breast cancer tumor response to the anticancer drug melphalanAcad Radiol201320415110.1016/j.acra.2012.08.005 FaniMMaeckeHRRadiopharmaceutical development of radiolabelled peptidesEur J Nucl Med Mol Imaging201239S11S3010.1007/s00259-011-2001-z GrigoryevDNLongBJNjarVCOBrodieAHMPregnenolone stimulates LNCaP prostate cancer cell growth via the mutated androgen receptorJ Steroid Biochem Mol Biol2000751101:CAS:528:DC%2BD3MXhvVeqsL0%3D10.1016/S0960-0760(00)00131-X MaddalenaMEFoxJChenJFengWCagnoliniALinderKETweedleMFNunnADLantryLE177Lu-AMBA biodistribution, radiotherapeutic efficacy, imaging, and autoradiography in prostate cancer models with low GRP-R expressionJ Nucl Med2009502017202410.2967/jnumed.109.064444 LambrechtFYDurkankBayrakELabeling bombesin-like peptide with 99mTc via hydrazinonicotinamide: description of optimized radiolabeling conditionsJ Radioanal Nucl Chem201028453954510.1007/s10967-010-0530-8 Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2013) GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC CancerBase No. 11 [Internet]. International Agency for Research on Cancer, Lyon. http://globocan.iarc.fr. Accessed 25 Sep 2014 FaniMMaeckeHROkarviSMRadiolabeled peptides: valuable tools for the detection and treatment of cancerTheranostics2012254815011:CAS:528:DC%2BC38XosVertrs%3D10.7150/thno.4024 de BarrosALBMotaLGSoaresDCFCoelhoMMAOliveiraMCCardosoVNTumor bombesin analog loaded long-circulating and pH-sensitive liposomes as tool for tumor identificationBioorg Med Chem Lett2011217373737510.1016/j.bmcl.2011.10.016 SchroederRPJvan WeerdenWMBangmaCKrenningEPde JongMPeptide receptor imaging of prostate cancer with radiolabelled bombesin analoguesMethods2009482002041:CAS:528:DC%2BD1MXmvFymtb0%3D10.1016/j.ymeth.2009.04.002 LearsKAFerdaniRLiangKZheleznyakAAndrewsRShermanCDAchilefuSAndersonCJRogersBEIn vitro and in vivo evaluation of 64Cu-labeled SarAr-bombesin analogs in gastrin-releasing peptide receptor–expressing prostate cancerJ Nucl Med2011524704771:CAS:528:DC%2BC3MXktVGnuro%3D10.2967/jnumed.110.082826 YuZCarlucciGAnaniasHJKDierckxRAJOLiuSHelfrichWWangFde JongIJElsingaPHEvaluation of a technetium-99m labeled bombesin homodimer for GRPR imaging in prostate cancerAmino Acids2013445435531:CAS:528:DC%2BC3sXhtFyitLY%3D10.1007/s00726-012-1369-9 LavermanPSosabowskiJKBoermanOCOyenWJGRadiolabelled peptides for oncological diagnosisEur J Nucl Med Mol Imaging201239S78S9210.1007/s00259-011-2014-7 de BarrosALBMotaLGFerreiraCACardosoVNKit formulation for 99mTc-labeling of HYNIC-βAla-Bombesin(7–14)Appl Radiat Isot2012702440244510.1016/j.apradiso.2012.06.022 SchotteliusMWesterHMolecular imaging targeting peptide receptorsMethods2009481611771:CAS:528:DC%2BD1MXmvFymtLc%3D10.1016/j.ymeth.2009.03.012 RPJ Schroeder (4030_CR9) 2009; 48 R Mansi (4030_CR21) 2011; 38 CL Santos-Cuevas (4030_CR31) 2009; 375 4030_CR1 KM Emonds (4030_CR15) 2009; 48 Z Yu (4030_CR7) 2013; 44 ALB Barros de (4030_CR24) 2010; 20 A Accardo (4030_CR8) 2014; 9 BL Faintuch (4030_CR27) 2008; 35 G Ferro-Flores (4030_CR3) 2010; 10 M Fani (4030_CR4) 2012; 2 P Laverman (4030_CR5) 2012; 39 M Fani (4030_CR11) 2012; 39 F Kong (4030_CR12) 2013; 20 ME Maddalena (4030_CR20) 2009; 50 ALB Barros de (4030_CR6) 2011; 21 LL Fuscaldi (4030_CR22) 2014; 300 J Shi (4030_CR33) 2008; 19 BJ Feldman (4030_CR16) 2001; 1 Y Xie (4030_CR18) 2007; 72 M Schottelius (4030_CR2) 2009; 48 FY Lambrecht (4030_CR14) 2013; 21 4030_CR23 FY Lambrecht (4030_CR13) 2010; 284 F Scopinaro (4030_CR28) 2003; 30 S Yu (4030_CR19) 2009; 11 KA Lears (4030_CR10) 2011; 52 J Nakashima (4030_CR30) 2004; 64 ALB Barros de (4030_CR25) 2012; 70 ALB Barros de (4030_CR26) 2013; 295 WT Phillips (4030_CR29) 1999; 37 CJ Smith (4030_CR32) 2003; 30 DN Grigoryev (4030_CR17) 2000; 75 |
| References_xml | – volume: 52 start-page: 470 year: 2011 ident: 4030_CR10 publication-title: J Nucl Med doi: 10.2967/jnumed.110.082826 contributor: fullname: KA Lears – volume: 64 start-page: 101 year: 2004 ident: 4030_CR30 publication-title: Urology doi: 10.1016/j.urology.2004.02.036 contributor: fullname: J Nakashima – ident: 4030_CR1 – volume: 39 start-page: S78 year: 2012 ident: 4030_CR5 publication-title: Eur J Nucl Med Mol Imaging doi: 10.1007/s00259-011-2014-7 contributor: fullname: P Laverman – volume: 21 start-page: 383 year: 2013 ident: 4030_CR14 publication-title: J Drug Target doi: 10.3109/1061186X.2012.757772 contributor: fullname: FY Lambrecht – volume: 48 start-page: 200 year: 2009 ident: 4030_CR9 publication-title: Methods doi: 10.1016/j.ymeth.2009.04.002 contributor: fullname: RPJ Schroeder – volume: 11 start-page: 39 year: 2009 ident: 4030_CR19 publication-title: Asian J Androl doi: 10.1038/aja.2008.44 contributor: fullname: S Yu – volume: 48 start-page: 161 year: 2009 ident: 4030_CR2 publication-title: Methods doi: 10.1016/j.ymeth.2009.03.012 contributor: fullname: M Schottelius – volume: 20 start-page: 6182 year: 2010 ident: 4030_CR24 publication-title: Bioorg Med Chem Lett doi: 10.1016/j.bmcl.2010.08.124 contributor: fullname: ALB Barros de – ident: 4030_CR23 – volume: 37 start-page: 13 year: 1999 ident: 4030_CR29 publication-title: Adv Drug Deliv Rev doi: 10.1016/S0169-409X(98)00108-2 contributor: fullname: WT Phillips – volume: 50 start-page: 2017 year: 2009 ident: 4030_CR20 publication-title: J Nucl Med doi: 10.2967/jnumed.109.064444 contributor: fullname: ME Maddalena – volume: 38 start-page: 97 year: 2011 ident: 4030_CR21 publication-title: Eur J Nucl Med Mol Imaging doi: 10.1007/s00259-010-1596-9 contributor: fullname: R Mansi – volume: 35 start-page: 401 year: 2008 ident: 4030_CR27 publication-title: Nucl Med Biol doi: 10.1016/j.nucmedbio.2008.02.005 contributor: fullname: BL Faintuch – volume: 48 start-page: 193 year: 2009 ident: 4030_CR15 publication-title: Methods doi: 10.1016/j.ymeth.2009.03.021 contributor: fullname: KM Emonds – volume: 72 start-page: 73 year: 2007 ident: 4030_CR18 publication-title: Mol Pharmacol doi: 10.1124/mol.107.033894 contributor: fullname: Y Xie – volume: 30 start-page: 861 year: 2003 ident: 4030_CR32 publication-title: Nucl Med Biol doi: 10.1016/S0969-8051(03)00116-1 contributor: fullname: CJ Smith – volume: 19 start-page: 1170 year: 2008 ident: 4030_CR33 publication-title: Bioconjug Chem doi: 10.1021/bc700471z contributor: fullname: J Shi – volume: 375 start-page: 75 year: 2009 ident: 4030_CR31 publication-title: Int J Pharm doi: 10.1016/j.ijpharm.2009.04.018 contributor: fullname: CL Santos-Cuevas – volume: 9 start-page: 1537 year: 2014 ident: 4030_CR8 publication-title: Int J Nanomed contributor: fullname: A Accardo – volume: 20 start-page: 41 year: 2013 ident: 4030_CR12 publication-title: Acad Radiol doi: 10.1016/j.acra.2012.08.005 contributor: fullname: F Kong – volume: 284 start-page: 539 year: 2010 ident: 4030_CR13 publication-title: J Radioanal Nucl Chem doi: 10.1007/s10967-010-0530-8 contributor: fullname: FY Lambrecht – volume: 1 start-page: 34 year: 2001 ident: 4030_CR16 publication-title: Nat Rev doi: 10.1038/35094009 contributor: fullname: BJ Feldman – volume: 21 start-page: 7373 year: 2011 ident: 4030_CR6 publication-title: Bioorg Med Chem Lett doi: 10.1016/j.bmcl.2011.10.016 contributor: fullname: ALB Barros de – volume: 30 start-page: 1378 year: 2003 ident: 4030_CR28 publication-title: Eur J Nucl Med Mol Imaging doi: 10.1007/s00259-003-1261-7 contributor: fullname: F Scopinaro – volume: 44 start-page: 543 year: 2013 ident: 4030_CR7 publication-title: Amino Acids doi: 10.1007/s00726-012-1369-9 contributor: fullname: Z Yu – volume: 39 start-page: S11 year: 2012 ident: 4030_CR11 publication-title: Eur J Nucl Med Mol Imaging doi: 10.1007/s00259-011-2001-z contributor: fullname: M Fani – volume: 75 start-page: 1 year: 2000 ident: 4030_CR17 publication-title: J Steroid Biochem Mol Biol doi: 10.1016/S0960-0760(00)00131-X contributor: fullname: DN Grigoryev – volume: 70 start-page: 2440 year: 2012 ident: 4030_CR25 publication-title: Appl Radiat Isot doi: 10.1016/j.apradiso.2012.06.022 contributor: fullname: ALB Barros de – volume: 2 start-page: 481 issue: 5 year: 2012 ident: 4030_CR4 publication-title: Theranostics doi: 10.7150/thno.4024 contributor: fullname: M Fani – volume: 300 start-page: 801 year: 2014 ident: 4030_CR22 publication-title: J Radioanal Nucl Chem doi: 10.1007/s10967-014-3040-2 contributor: fullname: LL Fuscaldi – volume: 295 start-page: 2083 year: 2013 ident: 4030_CR26 publication-title: J Radioanal Nucl Chem doi: 10.1007/s10967-012-2331-8 contributor: fullname: ALB Barros de – volume: 10 start-page: 87 year: 2010 ident: 4030_CR3 publication-title: Mini-Rev Med Chem doi: 10.2174/138955710791112596 contributor: fullname: G Ferro-Flores |
| SSID | ssj0009883 |
| Score | 2.1009881 |
| Snippet | Previous work revealed that 25-day tumour focus is the optimal developmental stage to assess LNCaP prostate tumour by scintigraphic images using technetium-99m... |
| SourceID | crossref springer |
| SourceType | Aggregation Database Publisher |
| StartPage | 379 |
| SubjectTerms | Chemistry Chemistry and Materials Science Diagnostic Radiology Hadrons Heavy Ions Inorganic Chemistry Nuclear Chemistry Nuclear Physics Physical Chemistry |
| Title | Feasibility of the 99mTc-HYNIC-βAla-Bombesin(7–14) for detection of LNCaP prostate tumour in experimental model |
| URI | https://link.springer.com/article/10.1007/s10967-015-4030-8 |
| Volume | 305 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV27TsMwFLWgDLDwRrzlgYGHjBI7ju2xLa0KqqpKgART5FckBE0r2g5s_AN_wofwEXwJdppAkWCAKYvz0PFN7nHu9TkAHBATWEylQgwrjCKpLJLUq4gar40uqNK5Z2TrknVu-FnDy-Tgz18X2f1pWZHMP9RTe91E7LskqVvykADxWTDnUg91sT1XbVy02l9Su3wivolJjCgjYVnL_Oki37PR91JonmGaS_95tmWwWPBJWJ0EwAqYsdkqmK-XNm5r4NGRvKIF9gn2U-gIHxSid6VR67ZzXkdvr9UHiWr9nncIyA7Z-_NLGB1Bx2WhsaO8USvz57U7ddmFA79JxNFTOBr33K3hXQanPQJgbqyzDq6bjat6CxVGC0j7JSriyquApV58HhOrKQmiULHAxG6uiKIqttpqLL0SvWWhMJimijHNuNBpqEVKNkAl62d2E8DUaK6wUJIzE4UyFtYRHkOUlDw1gdFb4LgEPBlM9DSSL-VkD2PiYEw8jAnfAicl3knxag1_H739p9E7YAH7Cct7-XZBZfQ4tntgdmjG-0VAuWPzvFPrfgDdcMcB |
| link.rule.ids | 315,782,786,27933,27934,41073,42142,48344,48347,48357,49649,49652,49662,52153 |
| linkProvider | Springer Nature |
| linkToHtml | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1JTsMwFLWgXcCGGVFGL1gwyFJiJ7G9LKWlFaVCokiwijxFQqJp1WHBjjtwEw7CITgJdpqoVIIF7J3Eev6xn_X_fw-AY6I9g0MhEcUSo0BIg0ToVES100bnoVSZZ2TzjnYe2GXdyeSQohcmq3YvUpLZTv2t2Y1HrkwytHce4iG2CMoBjwIbyuVqq3vVmGntsqn6JiYRCinxi2TmTy-ZP47mc6HZEdNY_dfk1sBKzihhdRoC62DBpBtgqVYYuW2CoaV5eRHsC-wn0FI-yHmvq1DzsdOqoY_36rNAF_2e8whIT-jn65sfnELLZqE246xUK3XPtTs1cQsHrk3EElQ4nvTsp-FTCr-7BMDMWmcL3Dfq3VoT5VYLSLlLKmLS6YAlTn4eE6NC4gW-pJ6O7GoRGcrIKKOwcFr0hvpc4zCRlCrKuEp8xROyDUppPzU7ACZaMYm5FIzqwBcRN5byaCKFYIn2tKqAswLxeDBV1Ihn2skOxtjCGDsYY1YB5wXecf5zjX4fvfun0Udgqdm9acftVud6Dyxjt3hZZd8-KI2HE3MAFkd6cphH1xeb_Mlf |
| linkToPdf | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3LSgMxFA1aQd34Ft9m4cIHoTPJzCRZSe2DVkspqKCrIa8BwU6LbRfu_Af_xA_xI_wSk-kMVdCFuM88OLkh53LvPQeAI6I9g0MhEcUSo0BIg0ToVES100bnoVSZZ2TzmnbuWK3uZHLOi1mYrNu9KElOZhqcSlM6Kg90Uv4y-MYj1zIZ2vyHeIjNgrnAJjI20Ocq9ctme6q7yyZKnJhEKKTELwqbP73k-9X0vS6aXTeN5X__6ApYypkmrExCYxXMmHQNLFQLg7d18GTpX94c-wz7CbRUEHLeu1Goed9pVdH7W-VRoIt-z3kHpMf04-XVD06gZblQm1HWwpW659qdqujCgRsfscQVjsY9-2n4kMKv7gEws9zZALeN-k21iXILBqRc8oqYdPpgiZOlx8SokHiBL6mnI7uLRIYyMsooLJxGvaE-1zhMJKWKMq4SX_GEbIJS2k_NFoCJVkxiLgWjOvBFxI2lQppIIViiPa22wWmBfjyYKG3EU01lB2NsYYwdjDHbBmcF9nF-6Ia_r9750-pDMN-tNeJ2q3O1Cxax27us4W8PlEZPY7MPZod6fJAH2idEgtIi |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Feasibility+of+the+99mTc-HYNIC-%CE%B2Ala-Bombesin%287%E2%80%9314%29+for+detection+of+LNCaP+prostate+tumour+in+experimental+model&rft.jtitle=Journal+of+radioanalytical+and+nuclear+chemistry&rft.au=Fuscaldi%2C+Leonardo+Lima&rft.au=de+Barros%2C+Andr%C3%A9+Lu%C3%ADs+Branco&rft.au=Santos%2C+Caiubi+Rodrigues+de+Paula&rft.au=de+Oliveira%2C+M%C3%B4nica+Cristina&rft.date=2015-08-01&rft.pub=Springer+Netherlands&rft.issn=0236-5731&rft.eissn=1588-2780&rft.volume=305&rft.issue=2&rft.spage=379&rft.epage=386&rft_id=info:doi/10.1007%2Fs10967-015-4030-8&rft.externalDocID=10_1007_s10967_015_4030_8 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0236-5731&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0236-5731&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0236-5731&client=summon |